Sign in Subscribe
Medical research

Mixodin Supplementation Shows Promise in Managing Migraine Symptoms

Strategic Insights

— 2 min read

Researchers at the Isfahan University of Medical Sciences in Iran have investigated the effects of mixodin, a novel bioactive formulation derived from natural compounds, on migraine symptoms. The study, published in the journal Trials, aimed to examine the combined therapeutic efficacy of curcumin, piperine, and gingerol in alleviating migraine-related symptoms. The researchers conducted a randomized, double-blind, placebo-controlled clinical trial involving 60 patients diagnosed with migraine, who were assigned to either receive mixodin supplementation or placebo capsules for 8 weeks. The results showed that mixodin supplementation significantly reduced clinical symptoms, mental health, and quality of life in patients with migraine, as well as serum levels of inflammatory markers and oxidative stress indicators.

Key Takeaways:

  • The study investigated the effects of mixodin supplementation on clinical symptoms, mental health, quality of life, inflammatory, and oxidative stress markers in patients with migraine.
  • The researchers found that mixodin supplementation significantly reduced clinical symptoms, mental health, and quality of life in patients with migraine.
  • The study used a randomized, double-blind, placebo-controlled clinical trial design, involving 60 patients diagnosed with migraine.
  • The intervention group received two mixodin capsules daily for 8 weeks, containing 300 mg of curcumin, 7.5 mg of gingerol, and 3.75 mg of piperine.
  • The control group received two placebo capsules daily for the same duration.
  • The primary outcome was the clinical symptoms of migraine, including frequency, severity, and duration of migraine attacks reported by patients.
  • Secondary outcomes included serum levels of hs-CRP, CGRP, TAC, TOS, MDA, SOD, NO, and assessments of mental health status and QOL.

Statistics:

  • 60 patients were recruited for the study, with 30 being assigned to the intervention group and 30 to the control group.
  • The study was conducted over 8 weeks, with recruitment beginning on November 11, 2024, and anticipated to be completed by June 22, 2025.
  • The study aims to evaluate the effects of mixodin supplementation on inflammatory markers, oxidative stress, migraine-related symptoms, mental health, and QOL in patients with migraine.
  • The results may provide insights into underlying mechanisms and support the development of evidence-based clinical guidelines for enhancing therapeutic outcomes in migraine management.

Sources:

  • Effect of mixodin supplementation on inflammatory and oxidative stress markers, clinical symptoms, mental health, and quality of life in patients with migraine: study protocol for a randomized clinical trial. Trials, 2025;26(1):430.
  • Iranian Registry of Clinical Trials (www.irct.ir) (ID: IRCT20241009063312N1). Registration date: 2024-12-15.
  • Bmc, Campus, 4 Crinan St, London N1 9XW, England. (BioMed Central - www.biomedcentral.com/; Trials - www.trialsjournal.com)
  • Mohammad Ali Askari, Student Research Committee, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Mahdi Vajdi, Fariborz Khorvash, and Afsaneh Yegdaneh, additional authors of the study.

Read more